SPARC signs pact with Bioprojet to acquire exclusive rights for drug to treat auto-immune diseases

"SPARC... announced that it has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet#39;s rights to the investigational medicinal product SCD-044," the company said.

from Moneycontrol Business News https://ift.tt/36QGuwQ